Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window
Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window
The time window for intravenous recombinant tissue plasminogen activator treatment in
 ischemic stroke patients has been extended to 4.5h. Little is known about intravenous
 recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese
 stroke patients. This exploratory study was to describe the feasibility and outcome of
 treatment with intravenous recombinant tissue plasminogen activator in the expanded time
 window, and to offer suggestions for future clinical work in China.
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was
 assessed by absolute changes in the National Institute of Health Stroke Scale score at 24
 hours and by the improvement of modified Rankin Scale score at discharge or 6-month
 follow-up. The safety of intravenous recombinant tissue plasminogen activator was assessed by
 the rate of mortality, intracerebral hemorrhage and other common complications. Multivariate
 logistic regression models were used to evaluate factors associated with favorable clinical
 outcome.
Inclusion Criteria:stroke patients in the 3-4.5 hour time window -

 Exclusion Criteria:stroke patients in more than 4.5 hour time window

 -